[go: up one dir, main page]

JP2004175790A - ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT - Google Patents

ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT Download PDF

Info

Publication number
JP2004175790A
JP2004175790A JP2003374551A JP2003374551A JP2004175790A JP 2004175790 A JP2004175790 A JP 2004175790A JP 2003374551 A JP2003374551 A JP 2003374551A JP 2003374551 A JP2003374551 A JP 2003374551A JP 2004175790 A JP2004175790 A JP 2004175790A
Authority
JP
Japan
Prior art keywords
acid
zinc
complex
vitamins
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003374551A
Other languages
Japanese (ja)
Inventor
Yoshitane Kojima
良種 小嶋
Yutaka Yoshikawa
豊 吉川
Taneyoshi Kajiwara
苗美 梶原
Hiroshi Taniguchi
洋 谷口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2003374551A priority Critical patent/JP2004175790A/en
Publication of JP2004175790A publication Critical patent/JP2004175790A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a specific healthy food product effective for preventing diabetes or a nutritive functional food product having an effect on health maintenance, by using a zinc (II) complex which is highly safe, even when administered for a long period, and has an α-glucosidase inhibitory effect as a substitute for zinc salts which are difficult to pass through a biomembrane and hardly absorbed by an organism, and to obtain a medicament by using the complex. <P>SOLUTION: The specific healthy food product effective for preventing the diabetes or the nutritive functional food product having the effect on the health maintenance is given by using the zinc (II) complex which is composed of ligands comprising compounds of amino acids, picolinic acids, vitamins, maltols, carboxylic acids, oligopeptides, and their derivatives, and a zinc source, and further has the α-glucosidase inhibitory effect. The medicament is obtained by using the complex. <P>COPYRIGHT: (C)2004,JPO

Description

本発明は、生体物質であるアミノ酸類、ビタミン類、ピコリン酸類、カルボン酸類、オリゴペプチド類、食品添加物であるマルトール類、及びそれらの誘導体からなる化合物を配位子として有する亜鉛（II）有機錯体に、生体物質であるアミノ酸類、ビタミン類、カルボン酸類などを含んでなる特定保健用食品、健康（機能）食品、栄養（機能）食品等の食品及び薬剤に関する。 The present invention relates to a zinc (II) organic compound having, as a ligand, a compound consisting of biological substances such as amino acids, vitamins, picolinic acids, carboxylic acids, oligopeptides, maltols as food additives, and derivatives thereof. The present invention relates to foods and drugs such as foods for specified health use, health (functional) foods, nutritional (functional) foods, and the like, which contain amino acids, vitamins, carboxylic acids, and the like as biological substances in the complex.

亜鉛イオンを用いたα−グルコシダーゼ阻害作用に関しては研究報告がなされている（非特許文献１）。しかし、亜鉛（II）イオン（硫酸亜鉛、酢酸亜鉛、塩化亜鉛）は無機塩であるため、生体膜の通過が難しく、生体内へ取り込まれにくい。そのような課題を克服するために、ほど良い安定性をもち、ほど良い脂溶性をもつa−グルコシダーゼ阻害作用を有する亜鉛（II）錯体としては、トラネキサム酸亜鉛化合物のみが知られている（特許文献１）。 Research reports have been made on the α-glucosidase inhibitory action using zinc ions (Non-Patent Document 1). However, since zinc (II) ions (zinc sulfate, zinc acetate, zinc chloride) are inorganic salts, they are difficult to pass through a biological membrane and are hardly taken into a living body. In order to overcome such problems, only zinc tranexamate compounds are known as zinc (II) complexes having moderate stability and moderate lipophilicity and having a-glucosidase inhibitory action (Patent Reference 1).

この発明に関する先行技術文献情報としては次のものがある。
Mechanism of glycogenosome formation in the sciatic nerve of cadmium-induced neuropathy. The inhibitory effect of cadmium ion on a-glucosidase, T. Iwamasa et al.,「医学のあゆみ」107, 13 (1978) トラネキサム酸亜鉛化合物を含む糖尿病治療薬、藤村、野崎、田中、特開2001−2427458 (P2001−247458A) Prior art document information relating to the present invention is as follows.
Mechanism of glycogenosome formation in the sciatic nerve of cadmium-induced neuropathy.The inhibitory effect of cadmium ion on a-glucosidase, T. Iwamasa et al., `` Ayumi of Medicine '' 107, 13 (1978) Antidiabetic drug containing zinc tranexamate compound, Fujimura, Nozaki, Tanaka, JP 2001-2427458 (P2001-247458A)

亜鉛（II）イオン（硫酸亜鉛、酢酸亜鉛、塩化亜鉛など）は無機塩であるため、生体膜の通過が難しく、生体内へ取り込まれにくい。その為、α−グルコシダーゼ阻害剤としての生理作用が発現しにくい。 Since zinc (II) ions (zinc sulfate, zinc acetate, zinc chloride, etc.) are inorganic salts, they are difficult to pass through a biological membrane and are hardly taken into a living body. Therefore, a physiological action as an α-glucosidase inhibitor is hardly exhibited.

そのような課題を克服するために、本発明は、亜鉛（II）イオンよりも毒性が低く、ほど良い安定性をもち、ほど良い脂溶性をもち、かつヒトにやさしい亜鉛（II）錯体として、生体物質であるアミノ酸類、ピコリン酸類、ビタミン類、カルボン酸類、オリゴペプチド類、食品添加物であるマルトール類、及びそれらの誘導体である化合物からなる配位子と亜鉛源とを含んでなるα−グルコシダーゼを阻害する亜鉛（II）錯体を用いる。
この発明が解決しようとしている課題は、前記、亜鉛（II）錯体を有効成分として含有する食品及び薬剤であり、α−グルコシダーゼ阻害作用を有する組成物に関する。
本発明の食品及び薬剤は、前記した亜鉛（II）錯体のほかに、さらに食品上及び薬剤上、許容される単体及びそれらの混合物を含有してなる食品及び薬剤が好ましい。 In order to overcome such a problem, the present invention provides a zinc (II) complex that is less toxic than zinc (II) ion, has good stability, has good lipophilicity, and is human-friendly. Α- comprising a ligand consisting of amino acids, picolinic acids, vitamins, carboxylic acids, oligopeptides, maltols as food additives, and derivatives thereof, which are biological substances, and a zinc source. A zinc (II) complex that inhibits glucosidase is used.
The problem to be solved by the present invention is a food and a drug containing the zinc (II) complex as an active ingredient, and relates to a composition having an α-glucosidase inhibitory action.
The food and drug of the present invention are preferably foods and drugs which further contain, in addition to the above-mentioned zinc (II) complex, an acceptable single substance and a mixture thereof on food and medicine.

本発明で用いられる亜鉛源としては、ヒト及び他の動物への投与に好適な亜鉛源であればどのようなものでもよいが、例えば、亜鉛の鉱産塩や亜鉛有機錯体などが好ましいものとして挙げられる。
亜鉛の鉱産塩としては、例えば、酢酸亜鉛、塩化亜鉛、硫酸亜鉛、硝酸亜鉛等が挙げられる。なお、亜鉛源として亜鉛の鉱産塩を使用した場合には、ｐH調整剤として、例えば、水酸化カリウム、水酸化ナトリウム、水酸化リチウム、水酸化バリウム等の塩基性水溶液や、クエン酸緩衝液、リン酸緩衝液等の緩衝液を併用してもよい。亜鉛（II）有機錯体としては、例えば、アミノ酸類、ピコリン酸類、ビタミン類、マルトール類、カルボン酸類、オリゴペプチド類、及びそれらの誘導体である化合物群より選ばれた配位子を有する亜鉛（II）有機錯体が好ましいものとして挙げられる。
本発明にかかる食品及び薬剤の形状は、粉末状、顆粒状、錠剤型、カプセル、液状、ゲル状、その他いずれのものでもよい。 As the zinc source used in the present invention, any zinc source suitable for administration to humans and other animals may be used.Examples include zinc mineral salts and zinc organic complexes. Can be
Examples of mineral salts of zinc include zinc acetate, zinc chloride, zinc sulfate, zinc nitrate and the like. In addition, when a mineral salt of zinc is used as a zinc source, as a pH adjuster, for example, a basic aqueous solution such as potassium hydroxide, sodium hydroxide, lithium hydroxide, barium hydroxide, a citrate buffer, A buffer such as a phosphate buffer may be used in combination. Examples of the zinc (II) organic complex include zinc (II) having a ligand selected from the group consisting of amino acids, picolinic acids, vitamins, maltols, carboxylic acids, oligopeptides, and compounds thereof. ) Organic complexes are preferred.
The shape of the food and drug according to the present invention may be powder, granule, tablet, capsule, liquid, gel, or any other form.

本発明に係る、亜鉛と錯体を形成し得る有機化合物と亜鉛源とを含んでなる食品及び薬剤は、亜鉛（II）イオンよりも毒性が低く、ほど良い安定性をもち、ほど良い脂溶性をもち、かつα−グルコシダーゼ阻害作用をもつ亜鉛（II）錯体を含んでなる食品及び薬剤として大いに期待されるものである。さらに、生活習慣病やその予備群などの健康状態を改善する食品及び薬剤として大いに期待される。 The food and drug according to the present invention comprising an organic compound capable of forming a complex with zinc and a zinc source are less toxic than zinc (II) ion, have good stability, and have good fat solubility. It is highly expected as a food and drug containing a zinc (II) complex having an α-glucosidase inhibitory action. Furthermore, it is expected as a food and a drug for improving health conditions such as lifestyle-related diseases and their spare groups.

本発明の亜鉛（II）錯体は、ほど良い安定性とほど良い脂溶性をもち、かつα−グルコシダーゼ阻害作用を有する。従って、本発明の亜鉛含有物は、食後に起こる高血糖を改善してインスリン需要を低減させ、糖代謝を改善し、糖尿病状態の改善が期待される。
また、本発明の錯体は、生体物質や食品添加物を配位子として用いており、長期間の摂取においても、実質的な副作用を伴わず安全である。 The zinc (II) complex of the present invention has good stability and good lipophilicity and has an α-glucosidase inhibitory action. Therefore, the zinc-containing substance of the present invention is expected to improve postprandial hyperglycemia, reduce insulin demand, improve glucose metabolism, and improve diabetes.
Further, the complex of the present invention uses a biological substance or a food additive as a ligand, and is safe without substantial side effects even during long-term ingestion.

以下の実施例は、この発明を説明するために示したものであり、本発明はこれらの実施例や試験例に限定されるものではない。 The following examples are provided for illustrating the present invention, and the present invention is not limited to these examples and test examples.

（薬理試験例１）
亜鉛(II)錯体の溶液（マウス体重１kg当たり５mg Znもしくは１０mg Znとなるような溶液）、それら亜鉛（II）錯体に対応する配位子の溶液、およびイオン交換水を調整し、実験日前日の深夜から約１２〜１４時間絶食させた２型糖尿病モデル動物であるKK-Ayマウスに投与した（−６０分と定義）。上記、溶液投与６０分後に、しょ糖溶液をマウス体重１kg当たり２gとなるように調整し、ゾンデを用いて投与した（０分と定義）。血糖値は、−６０分から測定をはじめ、０、１５、３０、６０、９０、１２０分（１２０分は測定していないものもある）まで測定した。 (Pharmacological test example 1)
A zinc (II) complex solution (solution of 5 mg Zn or 10 mg Zn per kg of mouse body weight), a ligand solution corresponding to the zinc (II) complex, and ion-exchanged water were prepared. Was administered to KK- Ay mice, a type 2 diabetes model animal that was fasted for about 12 to 14 hours from midnight (defined as -60 minutes). 60 minutes after the administration of the solution, the sucrose solution was adjusted to 2 g per 1 kg of mouse body weight, and administered using a sonde (defined as 0 minutes). The blood glucose level was measured from -60 minutes to 0, 15, 30, 60, 90, and 120 minutes (some 120 minutes were not measured).

上記、薬理試験例１に則り、被験物質である亜鉛（II）錯体、比較物質としてマルトール（mal）、グルタミン（Gln）、アルギニン（Arg）、カルニチン（Car）、ビタミンＣ（Vc）およびイオン交換水（コントロール群）をKK-Ayマウスに投与し、しょ糖負荷試験を行ったところ、コントロール群と比較して亜鉛（II）錯体投与群では血糖値の上昇が抑えられた（図１〜５）。また、マルトール、グルタミン酸、アルギニン、カルニチン、およびビタミンＣなどの配位子を投与した群では、コントロール群と比較すると若干の血糖値上昇抑制効果は観測されたが、特記すべきほどの変化は見られなかった。
これらのことから、亜鉛（II）錯体はα−グルコシダーゼ阻害作用を有しており、それらの効果は、配位子のみを投与したときと比較して、高いα−グルコシダーゼ阻害作用を有していることが証明された。
以上の結果から、亜鉛（II）錯体は、亜鉛の補給とα−グルコシダーゼ阻害作用との両方を兼ね備えた化合物であり、糖尿病状態を改善させる効果が期待される。 According to the above pharmacological test example 1, a zinc (II) complex as a test substance, maltol (mal), glutamine (Gln), arginine (Arg), carnitine (Car), vitamin C (Vc), and ion exchange as comparative substances When water (control group) was administered to KK- Ay mice and a sucrose tolerance test was performed, an increase in blood glucose level was suppressed in the zinc (II) complex-administered group as compared to the control group (FIGS. 1 to 5). ). In the group to which ligands such as maltol, glutamic acid, arginine, carnitine, and vitamin C were administered, the effect of suppressing a slight increase in blood glucose level was observed as compared with the control group, but a remarkable change was not observed. I couldn't.
From these facts, the zinc (II) complex has an α-glucosidase inhibitory effect, and the effect of the zinc (II) complex is higher than when only the ligand is administered. Proven to be.
From the above results, the zinc (II) complex is a compound having both zinc supplementation and α-glucosidase inhibitory activity, and is expected to have an effect of improving the diabetic state.

（薬理試験例２）
α―グルコシダーゼ阻害活性の検討は、特開2002-316939に記載の、Dehiqvistの方法を改良して行った。
0.1 M基質（マルトース、スクロースを0.15M HEPES緩衝液pH 6.8に溶解したもの）溶液、または4%デンプン溶液（0.15M HEPES緩衝液pH 6.8に溶解したもの）0.1 mlに、被験物質溶液0.1 ml、および酵素液0.1 mlを加え、37℃ 60分間反応させたあと、煮沸させ、反応を停止した。生じたグルコース量は、グルコースオキシダーゼ法（グルコースCIIテストワコー）により測定した。空試験として、基質溶液の代わりに、0.15 M HEPES緩衝液（pH=6.8）を加えて、同様の試験を行った時の吸光度をブランク値とし、この値を差し引き、試験液Asを求めた。なお、酵素液は市販のα―グルコシダーゼ（和光純薬工業社製）を、0.015 M HEPES緩衝液（pH=6.8）で5 units／mlに調整したものを用いた。また、対照としては、被験物質の代わりに、溶媒を加えた時の吸光度Acを測定し、下式によって、αグルコシダーゼ阻害活性を測定した（図６と７）。
α−グルコシダーゼ阻害活性(%)=[（Ac―As）／Ac]×100 (Pharmacological test example 2)
The α-glucosidase inhibitory activity was examined by improving the Dehiqvist method described in JP-A-2002-316939.
0.1 ml of a 0.1 M substrate (maltose, sucrose dissolved in 0.15 M HEPES buffer pH 6.8) solution or 0.1 ml of 4% starch solution (dissolved in 0.15 M HEPES buffer pH 6.8), 0.1 ml of the test substance solution, After adding 0.1 ml of the enzyme solution and reacting at 37 ° C. for 60 minutes, the mixture was boiled to stop the reaction. The amount of generated glucose was measured by a glucose oxidase method (Glucose CII Test Wako). As a blank test, a 0.15 M HEPES buffer (pH = 6.8) was added instead of the substrate solution, and the absorbance at the time of performing the same test was used as a blank value, and this value was subtracted to obtain a test solution As. As the enzyme solution, a commercially available α-glucosidase (manufactured by Wako Pure Chemical Industries, Ltd.) adjusted to 5 units / ml with 0.015 M HEPES buffer (pH = 6.8) was used. As a control, the absorbance Ac when a solvent was added instead of the test substance was measured, and the α-glucosidase inhibitory activity was measured by the following formula (FIGS. 6 and 7).
α-Glucosidase inhibitory activity (%) = [(Ac-As) / Ac] × 100

上記、薬理試験例２に則り、被験物質である亜鉛（II）錯体のα−グルコシダーゼ阻害活性を測定し、IC50値を求めると、表１および表２に示す濃度が得られた。
図６と７に示すように、ビス（ビタミンＣ）／亜鉛(II)錯体、Zn(Vc)2、は、濃度依存的にα−グルコシダーゼ阻害活性を有することが明らかになった。 Above, pursuant to Pharmacological Test Example 2, by measuring the α- glucosidase inhibitory activity of zinc (II) complex of the test substance, when determining an IC 50 value, the concentration shown in Table 1 and Table 2 were obtained.
As shown in FIGS. 6 and 7, it was revealed that the bis (vitamin C) / zinc (II) complex, Zn (Vc) 2 , had an α-glucosidase inhibitory activity in a concentration-dependent manner.

Figure 2004175790
Figure 2004175790

Figure 2004175790
Figure 2004175790

マルトール（mal、×）、Zn(mal)2錯体（１０mg Zn / kg：＊）、及び水（コントロール群：●）を−６０分に投与し、０分にしょ糖を体重１kgあたり２g投与したときの糖負荷試験の結果。When maltol (mal, ×), Zn (mal) 2 complex (10 mg Zn / kg: *), and water (control group: ●) are administered at -60 minutes, and sucrose is administered at 2 g per kg of body weight in 0 minutes. Of glucose tolerance test. L−グルタミン（Gln、◇）及びZn(Gln)2錯体（１０mg Zn / kg：◆）を−６０分に投与し、０分にしょ糖を体重１kgあたり２g投与したときの糖負荷試験の結果。The result of the glucose tolerance test when L-glutamine (Gln, ◇) and Zn (Gln) 2 complex (10 mg Zn / kg: ◆) were administered at -60 minutes, and sucrose was administered at 2 g per kg of body weight at 0 minutes. L―アルギニン（Arg、−）、Zn(Arg)2Cl2錯体（１０mg Zn / kg：＋）、及び水（コントロール群：●）を−６０分に投与し、０分にしょ糖を体重１kgあたり２g投与したときの糖負荷試験の結果。L- arginine (Arg, -), Zn ( Arg) 2 Cl 2 complex (10mg Zn / kg: +) , and water (control group: ●) was administered to -60 minutes, per body weight 1kg sucrose 0 minutes Results of glucose tolerance test when 2 g was administered. カルニチン（Car、□）及びZn(Car)2Cl2錯体（５mg Zn / kg：■）を−６０分に投与し、０分にしょ糖を体重１kgあたり２g投与したときの糖負荷試験の結果。The results of a glucose tolerance test when carnitine (Car, □) and Zn (Car) 2 Cl 2 complex (5 mg Zn / kg: ■) were administered at -60 minutes, and sucrose was administered at 2 g per kg of body weight at 0 minutes. ビタミンC（Vc、△）、Zn(Vc)Cl錯体（１０mg Zn / kg：▲）、及び水（コントロール群：●）を−６０分に投与し、０分にしょ糖を体重１kgあたり２g投与したときの糖負荷試験の結果。Vitamin C (Vc, △), Zn (Vc) Cl complex (10 mg Zn / kg:）), and water (control group: ●) were administered for -60 minutes, and sucrose was administered at 0 g for 2 g per 1 kg of body weight. The results of the glucose tolerance test. 基質にマルトースを用いたときの、Zn(Vc)2錯体の濃度（mM）とα-グルコシダーゼ阻害率（％）との関係を示す。4 shows the relationship between Zn (Vc) 2 complex concentration (mM) and α-glucosidase inhibition rate (%) when maltose is used as a substrate. 基質にスクロースを用いたときの、Zn(Vc)2錯体の濃度（mM）とα-グルコシダーゼ阻害率（％）との関係を示す。3 shows the relationship between the concentration (mM) of Zn (Vc) 2 complex and α-glucosidase inhibition rate (%) when sucrose was used as a substrate.

Claims (12)

亜鉛と錯体を形成し得る、アミノ酸類、ピコリン酸類、ビタミン類、マルトール類、カルボン酸類、オリゴペプチド類、及びそれらの誘導体である化合物からなる配位子と亜鉛源とを含んでなるα−グルコシダーゼ阻害剤として安全に健康を保てる食品。 Α-Glucosidase comprising a ligand capable of forming a complex with zinc, comprising a ligand consisting of amino acids, picolinic acids, vitamins, maltols, carboxylic acids, oligopeptides, and their derivatives, and a zinc source Foods that can keep your health safe as an inhibitor. 亜鉛源が亜鉛の鉱産塩又は有機錯体である請求項１に記載の食品。 The food according to claim 1, wherein the zinc source is a mineral salt or an organic complex of zinc. アミノ酸類が、スレオニン、バリン、ロイシン、イソロイシン、グリシン、プロリン、アルギニン、グルタミン、グルタミン酸、アスパラギン、アスパラギン酸、アラニン、ヒスチジン、リジン、セリン、メチオニン、フェニルアラニン、チロシン、システイン、トリプトファン、ベタイン、テアニン、及びそれらアミド類などの誘導体からなる群より選ばれた１種又は２種以上の化合物である請求項１と２に記載の食品。 Amino acids are threonine, valine, leucine, isoleucine, glycine, proline, arginine, glutamine, glutamic acid, asparagine, aspartic acid, alanine, histidine, lysine, serine, methionine, phenylalanine, tyrosine, cysteine, tryptophan, betaine, theanine, and 3. The food according to claim 1, which is one or more compounds selected from the group consisting of derivatives such as amides. ピコリン酸類が、ピコリン酸、３−及び６−メチルピコリン酸、３−、４−及び６−ハロゲノピコリン酸、及びそれらのアミドなどの誘導体からなる群より選ばれた１種又は２種以上の化合物である請求項１と２に記載の食品。 One or more compounds in which the picolinic acid is selected from the group consisting of picolinic acid, 3- and 6-methylpicolinic acid, 3-, 4- and 6-halogenopicolinic acid, and derivatives thereof such as amides The food according to claim 1, wherein the food is: ビタミン類が、ビタミンB複合体であるニコチン酸やニコチンアミド、ビタミンU、アスコルビン酸、カルニチン、葉酸、リボフラビン及びそれらの混合物からなる請求項１と２に記載の食品。 3. The food according to claim 1, wherein the vitamins comprise nicotinic acid or nicotinamide, which is a vitamin B complex, vitamin U, ascorbic acid, carnitine, folic acid, riboflavin, and a mixture thereof. マルトール類が、マルトール、コウジ酸又はそれらの混合物からなる請求項１と２に記載の食品。 The food according to claim 1 or 2, wherein the maltols comprise maltol, kojic acid or a mixture thereof. カルボン酸類が、酢酸、プロピオン酸、オキシカルボン酸、クエン酸、マロン酸、リンゴ酸、乳酸、サリチル酸、グルコン酸、ウロン酸、及びそれらの混合物からなる請求項１と２に記載の食品。 The food according to claim 1, wherein the carboxylic acids comprise acetic acid, propionic acid, oxycarboxylic acid, citric acid, malonic acid, malic acid, lactic acid, salicylic acid, gluconic acid, uronic acid, and a mixture thereof. オリゴペプチド類が、ジペプチド類及びトリペプチド類、又はそれらの誘導体からなる群から選ばれた１種又は２種以上の化合物である請求項１と２に記載の食品。 3. The food according to claim 1, wherein the oligopeptide is one or more compounds selected from the group consisting of dipeptides and tripeptides, or derivatives thereof. 更に、他の食品類、食品添加物類、ビタミン類及びミネラル類を含んでなるα−グルコシダーゼ阻害剤として安全に予防できる食品。 Further, a food which can be safely prevented as an α-glucosidase inhibitor comprising other foods, food additives, vitamins and minerals. 亜鉛と錯体を形成し得る、アミノ酸類、ピコリン酸類、ビタミン類、マルトール類、カルボン酸類、オリゴペプチド類、及びそれらのアミド類などの誘導体である化合物からなる配位子と亜鉛源とを含んでなるα−グルコシダーゼ阻害剤として安全に治療・予防できる薬剤。 Includes a zinc source and a ligand that can form a complex with zinc, which is a derivative of a compound such as amino acids, picolinic acids, vitamins, maltols, carboxylic acids, oligopeptides, and amides thereof. Which can be safely treated and prevented as an α-glucosidase inhibitor. アミノ酸類、ピコリン酸類、ビタミン類、マルトール類、カルボン酸類、オリゴペプチド類、及びそれらの誘導体を有する有機物が、請求項３〜８に記載の群から選ばれた１種、又は２種以上の化合物である請求項１０に記載の薬剤。 An organic substance having amino acids, picolinic acids, vitamins, maltols, carboxylic acids, oligopeptides, and derivatives thereof, one or more compounds selected from the group of claims 3 to 8. The drug according to claim 10, which is: 更に、他の食品類、食品添加物類、ビタミン類及びミネラル類を含んでなるα−グルコシダーゼ阻害剤として安全に治療・予防できる薬剤。






Further, a drug which can be safely treated and prevented as an α-glucosidase inhibitor comprising other foods, food additives, vitamins and minerals.






JP2003374551A 2002-11-12 2003-11-04 ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT Pending JP2004175790A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003374551A JP2004175790A (en) 2002-11-12 2003-11-04 ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002327684 2002-11-12
JP2003374551A JP2004175790A (en) 2002-11-12 2003-11-04 ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT

Publications (1)

Publication Number Publication Date
JP2004175790A true JP2004175790A (en) 2004-06-24

Family

ID=32716133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003374551A Pending JP2004175790A (en) 2002-11-12 2003-11-04 ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT

Country Status (1)

Country Link
JP (1) JP2004175790A (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043606A1 (en) * 2005-10-12 2007-04-19 Genolac Bl Corporation Antidiabetic agent comprising anionic polyamino acid-metal complex
WO2009123364A1 (en) * 2008-04-03 2009-10-08 Fujifilm Corporation Mineral absorption accelerator and iron deficiency anemia improver or food composition
CN103156171A (en) * 2011-12-12 2013-06-19 朱兵 Slimming tablet and preparation method thereof
CN103156170A (en) * 2011-12-12 2013-06-19 朱兵 Blood sugar-reducing tablet and preparation method thereof
WO2014098828A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Teeth whitening methods, visually perceptible signals and compositions therefor|comprising zinc amino acid halides
WO2014098814A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Composition with zinc amino acid/trimethylglycine halide precursors
WO2014098826A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Oral care compositions comprising zinc amino acid halides
WO2014098813A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Zinc amino acid/trimethylglycine halide
WO2014098824A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Oral gel comprising zinc - amino acid complex
WO2014098822A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Zinc amino acid halide mouthwashes
WO2014099226A3 (en) * 2012-12-19 2014-09-25 Colgate-Palmolive Company Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
WO2014204439A1 (en) * 2013-06-18 2014-12-24 Colgate-Palmolive Company Zinc amino acid halide complex with cysteine
JP2015117212A (en) * 2013-12-19 2015-06-25 二村　芳弘 Uronic acid derivative which shows longevity gene sirt1 activating action adapting health care culture, and production method thereof
WO2015195491A1 (en) * 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9498421B2 (en) 2012-12-19 2016-11-22 Colgate-Palmolive Company Two component compositions containing tetrabasic zinc-amino acid halide complexes and cysteine
US9504858B2 (en) 2012-12-19 2016-11-29 Colgate-Palmolive Company Zinc amino acid halide complex with cysteine
US9675823B2 (en) 2012-12-19 2017-06-13 Colgate-Palmolive Company Two component compositions containing zinc amino acid halide complexes and cysteine
US9750670B2 (en) 2012-12-19 2017-09-05 Colgate-Palmolive Company Zinc amino acid complex with cysteine
US9757316B2 (en) 2012-12-19 2017-09-12 Colgate-Palmolive Company Zinc-lysine complex
US9775792B2 (en) 2012-12-19 2017-10-03 Colgate-Palmolive Company Oral care products comprising a tetrabasic zinc-amino acid-halide complex
US9827177B2 (en) 2012-12-19 2017-11-28 Colgate-Palmolive Company Antiperspirant products with protein and antiperspirant salts
US9861563B2 (en) 2012-12-19 2018-01-09 Colgate-Palmolive Company Oral care products comprising tetrabasic zinc chloride and trimethylglycine
US9901523B2 (en) 2012-12-19 2018-02-27 Colgate-Palmolive Company Oral care products comprising zinc oxide and trimethylglycine
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US10188112B2 (en) 2012-12-19 2019-01-29 Colgate-Palmolive Company Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
WO2020131665A1 (en) * 2018-12-21 2020-06-25 Colgate-Palmolive Company Zinc-arginine-halide complex

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043606A1 (en) * 2005-10-12 2007-04-19 Genolac Bl Corporation Antidiabetic agent comprising anionic polyamino acid-metal complex
WO2009123364A1 (en) * 2008-04-03 2009-10-08 Fujifilm Corporation Mineral absorption accelerator and iron deficiency anemia improver or food composition
CN103156171A (en) * 2011-12-12 2013-06-19 朱兵 Slimming tablet and preparation method thereof
CN103156170A (en) * 2011-12-12 2013-06-19 朱兵 Blood sugar-reducing tablet and preparation method thereof
US9757316B2 (en) 2012-12-19 2017-09-12 Colgate-Palmolive Company Zinc-lysine complex
RU2648513C2 (en) * 2012-12-19 2018-03-26 Колгейт-Палмолив Компани Zinc amino acid halide mouthwash
WO2014098826A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Oral care compositions comprising zinc amino acid halides
WO2014098813A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Zinc amino acid/trimethylglycine halide
WO2014098824A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Oral gel comprising zinc - amino acid complex
WO2014098822A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Zinc amino acid halide mouthwashes
WO2014099226A3 (en) * 2012-12-19 2014-09-25 Colgate-Palmolive Company Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
WO2014099166A3 (en) * 2012-12-19 2014-10-16 Colgate-Palmolive Company Two component compositions containing zinc amino acid halide complexes and cysteine
US11197811B2 (en) 2012-12-19 2021-12-14 Colgate-Palmolive Company Teeth whitening methods, visually perceptible signals and compositions therefor
US10792236B2 (en) 2012-12-19 2020-10-06 Colgate-Palmolive Company Dentifrice comprising zinc-amino acid complex
CN104853721A (en) * 2012-12-19 2015-08-19 高露洁-棕榄公司 Zinc amino acid/trimethylglycine halide
CN104853723A (en) * 2012-12-19 2015-08-19 高露洁-棕榄公司 Oral gel comprising zinc - amino acid complex
KR20150097491A (en) * 2012-12-19 2015-08-26 콜게이트-파아므올리브캄파니 Zinc amino acid complex with cysteine
KR20150097505A (en) * 2012-12-19 2015-08-26 콜게이트-파아므올리브캄파니 Zinc amino acid halide complex with cysteine
AU2012397254B2 (en) * 2012-12-19 2015-09-17 Colgate-Palmolive Company Zinc amino acid/trimethylglycine halide
AU2012397263B2 (en) * 2012-12-19 2015-09-24 Colgate-Palmolive Company Zinc amino acid halide mouthwashes
AU2012397267B2 (en) * 2012-12-19 2015-10-08 Colgate-Palmolive Company Oral care compositions comprising zinc amino acid halides
AU2012397269B2 (en) * 2012-12-19 2015-10-29 Colgate-Palmolive Company Teeth whitening methods, visually perceptible signals and compositions therefor|comprising zinc amino acid halides
KR102161832B1 (en) 2012-12-19 2020-10-06 콜게이트-파아므올리브캄파니 Zinc amino acid complex with cysteine
JP2016504996A (en) * 2012-12-19 2016-02-18 コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ Zinc amino acid halide complexes with cysteine
AU2012397265B2 (en) * 2012-12-19 2016-02-25 Colgate-Palmolive Company Oral gel comprising zinc - amino acid complex
US9498421B2 (en) 2012-12-19 2016-11-22 Colgate-Palmolive Company Two component compositions containing tetrabasic zinc-amino acid halide complexes and cysteine
US9504858B2 (en) 2012-12-19 2016-11-29 Colgate-Palmolive Company Zinc amino acid halide complex with cysteine
US9572756B2 (en) 2012-12-19 2017-02-21 Colgate-Palmolive Company Teeth whitening methods, visually perceptible signals and compositions therefor
US9675823B2 (en) 2012-12-19 2017-06-13 Colgate-Palmolive Company Two component compositions containing zinc amino acid halide complexes and cysteine
RU2625757C2 (en) * 2012-12-19 2017-07-18 Колгейт-Палмолив Компани Cleansing compositions for personal use which consist of amino acid halogenide/trimethylglycine zinc
US10610475B2 (en) 2012-12-19 2020-04-07 Colgate-Palmolive Company Teeth whitening methods, visually perceptible signals and compositions therefor
US9750670B2 (en) 2012-12-19 2017-09-05 Colgate-Palmolive Company Zinc amino acid complex with cysteine
WO2014098828A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Teeth whitening methods, visually perceptible signals and compositions therefor|comprising zinc amino acid halides
US9827177B2 (en) 2012-12-19 2017-11-28 Colgate-Palmolive Company Antiperspirant products with protein and antiperspirant salts
WO2014098814A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Composition with zinc amino acid/trimethylglycine halide precursors
US9775792B2 (en) 2012-12-19 2017-10-03 Colgate-Palmolive Company Oral care products comprising a tetrabasic zinc-amino acid-halide complex
US9763865B2 (en) 2012-12-19 2017-09-19 Colgate-Palmolive Company Oral gel comprising zinc-amino acid complex
US9861563B2 (en) 2012-12-19 2018-01-09 Colgate-Palmolive Company Oral care products comprising tetrabasic zinc chloride and trimethylglycine
US9901523B2 (en) 2012-12-19 2018-02-27 Colgate-Palmolive Company Oral care products comprising zinc oxide and trimethylglycine
RU2636226C2 (en) * 2012-12-19 2017-11-21 Колгейт-Палмолив Компани Gel for oral care, containing zinc complex and amino acids
US9925130B2 (en) 2012-12-19 2018-03-27 Colgate-Palmolive Company Composition with zinc amino acid/trimethylglycine halide precursors
US9943473B2 (en) 2012-12-19 2018-04-17 Colgate-Palmolive Company Zinc lysine halide complex
US9980890B2 (en) 2012-12-19 2018-05-29 Colgate-Palmolive Company Zinc amino acid halide mouthwashes
US9993407B2 (en) 2012-12-19 2018-06-12 Colgate-Palmolive Company Teeth whitening methods, visually perceptible signals and compositions therefor
US10610470B2 (en) 2012-12-19 2020-04-07 Colgate-Palmolive Company Oral care composition zinc-lysine complex
CN104853724B (en) * 2012-12-19 2018-07-24 高露洁-棕榄公司 Zinc and amino-acids halide collutory
US10105303B2 (en) 2012-12-19 2018-10-23 Colgate-Palmolive Company Oral care composition comprising zinc amino acid halides
US10588841B2 (en) 2012-12-19 2020-03-17 Colgate-Palmolive Company Oral care compositions comprising zinc amino acid halides
US10188112B2 (en) 2012-12-19 2019-01-29 Colgate-Palmolive Company Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
US10195125B2 (en) 2012-12-19 2019-02-05 Colgate-Palmolive Company Oral care composition comprising zinc-lysine complex
US10245222B2 (en) 2012-12-19 2019-04-02 Colgate-Palmolive Company Dentifrice comprising zinc-amino acid complex
KR102030761B1 (en) * 2012-12-19 2019-10-10 콜게이트-파아므올리브캄파니 Zinc amino acid halide complex with cysteine
US10524995B2 (en) 2012-12-19 2020-01-07 Colgate-Palmolive Company Zinc amino acid halide mouthwashes
WO2014204439A1 (en) * 2013-06-18 2014-12-24 Colgate-Palmolive Company Zinc amino acid halide complex with cysteine
JP2015117212A (en) * 2013-12-19 2015-06-25 二村　芳弘 Uronic acid derivative which shows longevity gene sirt1 activating action adapting health care culture, and production method thereof
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
CN107074884A (en) * 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 Active Mineral Amino Acid Complex
WO2015195491A1 (en) * 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11135298B2 (en) 2016-06-03 2021-10-05 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11191840B2 (en) 2016-06-03 2021-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11925688B2 (en) 2016-06-03 2024-03-12 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
WO2020131665A1 (en) * 2018-12-21 2020-06-25 Colgate-Palmolive Company Zinc-arginine-halide complex
US10952943B2 (en) 2018-12-21 2021-03-23 Colgate-Palmolive Company Zinc-arginine-chloride complex
US11826448B2 (en) 2018-12-21 2023-11-28 Colgate-Palmolive Company Zinc-arginine-chloride complex

Similar Documents

Publication Publication Date Title
JP2004175790A (en) ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT
KR100613037B1 (en) Chromium (III) alpha amino acid complex
Martin Bioinorganic chemistry of metal ion toxicity
AU572927B2 (en) Dietary mixture of salts
MX2010009075A (en) Folates, compositions and uses thereof.
US20050260277A1 (en) Method and formula for anti-tumor and anti-matastatic effect
RU2007136761A (en) SALTS, ADDITIVE PRODUCTS AND COMPLEX COMPOUNDS OF GUANIDINE ACID ACID
Abakumova et al. Anticancer activity of oxovanadium compounds
JPS62270522A (en) Nutritional supplements to treat uremia
JP5290975B2 (en) Calcium L-carnitine fumarate and production method and use thereof
WAKAMIYA et al. Vitamin C activity of 2-O-α-D-glucopyranosyl-L-ascorbic acid in guinea pigs
WO1994017794A1 (en) Blends of glycine derivatives and sugars
JP2003319760A (en) Zinc-containing substance having anti-obesity function
WO2013039211A1 (en) Solid composition
WO2001015745A1 (en) Method and formula for tumor remission and suppression of cancer
WO2007117771A2 (en) Time-release compositions for delivery of [cr3o(carboxylate)6(h2o)3]+
JP2004166690A (en) Zinc-containing product having antioxidative effect
US5665385A (en) Dietary metal supplements
WO2004052123A1 (en) Zinc-rich foods having effect of preventing diabetes
JP3769267B2 (en) Zinc-enhanced food and method for producing the same
JPWO2002089606A1 (en) Zinc-containing food
US6149948A (en) Method of decreasing plasma cholesterol and triglycerides with a chromium-containing complex
JP7672493B2 (en) Methods for Treating Pain with Vanadium Compounds
RU2262868C2 (en) Food biologically active additive
Eliason et al. The anti‐tumor arotinoid RO 40‐8757 protects bone marrow from the toxic effects of cyclophosphamide

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070508

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070709

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080108